Eric Lightcap

About Eric Lightcap

I am a passionate, independent, and accomplished scientist and leader with 27 years of experience in oncology and immuno-oncology drug discovery. I have worked extensively within matrixed environments, from small biotech to large pharmaceutical, and have built strong, mutually beneficial relationships with multiple contract research organizations. I have a successful history of applying mechanistic studies to highly novel therapies, leveraging insights from functional and correlative genomics with in vitro, ex vivo and in vivo studies, to inform the translation of multiple small molecule oncology assets into the clinic, resulting in multiple conference presentations and publications. These genetic studies enabled me to explore diverse and unexpected biology, substantially broadening my understanding of cancer. I have served on multiple phase 1 clinical teams to oversee the successful development and application of blood- and tumor-based pharmacodynamic and predictive biomarkers, including for HC-5404, HC-7366, Velcade, pevonedistat, subasumstat, and TAK-676. Highlights:• Clinical pharmacodynamics of bortezomib (PS-341, Velcade)• Identification of combination partners for pevonedistat (MLN4924)• Redirection of subasumstat (TAK-981) to clinical exploration as an innate immune stimulatorI aspire to leverage my background in• Oncology• Immuno-oncology• Innovative drug discovery and strong science• Forward translation• Reverse translation• Predictive and pharmacodynamic biomarker development, both blood- and tumor-based• Genomics• Computational biology and bioinformatics• Experimental design, data analysis and interpretationScientific Focus: • Translation of integrated stress response modulators for the treatment of cancer, October 2021-Present• Immuno-oncology target identification and translation, March 2017-September 2021• Application of ‘omic technologies to characterize oncology clinical potential of agents targeting protein homeostasis, October 2001-March 2017• Identification and characterization of inhibitors of ubiquitin-proteasome system, July 1997-September 2001

Experience

1. Vice President

   Hibercell

   Oct 2023 — Present · Boston, MA, US

Education

• University of Wisconsin-Madison

  Ph.D., Biochemistry

  1985 — 1991

• Northwestern University

  Postdoctoral Fellow, Chemistry

  1991 — 1994

• Indiana University Bloomington

  B.S., Biochemistry

  1982 — 1985